Certara Stock Fell 23% After Earnings and This Fund Bought Up $3 Million Anyway

Certara, Inc. operates at scale within the healthcare information services sector, leveraging advanced biosimulation and regulatory expertise to accelerate drug development. Its integrated software and service offerings support clients from early-stage research through regulatory submission and commercialization. The company's global footprint and specialized focus provide a competitive advantage in the pharmaceutical R&D technology market.As of Friday, Certara shares were priced at $8.74, down 18% over the ...